A BridgeBio Pharma drug developed for an more and more prevalent cardiovascular situation has gained FDA approval, marking a comeback for a corporation and a molecule with a turbulent historical past. However BridgeBio’s challenges aren’t over. The biotech’s new product should now compete in opposition to a blockbuster Pfizer treatment already nicely established as the usual of care and fend off new competitors on the best way.
The late Friday approval for the drug, acoramidis, covers the remedy of adults with cardiomyopathy brought on by transthyretin-mediated amyloidosis, or ATTR. The illness stems from a genetic mutation although it may possibly additionally develop as a consequence of growing older. The FDA approval covers each sorts. BridgeBio’s twice-daily capsule will likely be marketed underneath the model identify Attruby.
In ATTR, irregular variations of a liver protein known as transthyretin result in a buildup of amyloid protein in tissues and organs. When this buildup impacts the center, it may possibly result in cardiomyopathy, making it more durable for the organ to pump blood. Attruby is a small molecule designed to bind to the irregular TTR, stabilizing the protein and stopping it from resulting in the amyloid buildup characterised by the illness. Pfizer’s ATTR cardiomyopathy drug, tafamidis, authorized in 2019 and marketed because the four-times each day capsule Vyndaqel and the once-daily capsule Vyndamax, can also be a TTR stabilizer. However Palo Alto, California-based BridgeBio got down to present its drug is the higher stabilizer. That effort was nearly derailed.
Almost three years in the past, BridgeBio reported preliminary knowledge displaying its drug didn’t beat a placebo within the first a part of a Section 3 scientific trial, which assessed sufferers after 12 months. The corporate attributed the failure to a excessive placebo response. The disappointing outcomes sank shares of the biotech by greater than 70%. However the research’s design included a second half that will assess sufferers after 30 months of remedy. BridgeBio opted to proceed the research, hoping longer remedy would result in higher outcomes.
FDA approval of Attruby is predicated on the 30-month knowledge from the Section 3 research, which enrolled 632 sufferers with ATTR cardiomyopathy. Outcomes confirmed the drug met the principle objective of displaying statistically important enchancment on a composite endpoint comprised of 4 measures of the illness. The outcomes had been printed within the New England Journal of Medication early this yr. Talking throughout a Friday night webcast, BridgeBio CEO Neil Kumar drew distinctions between Attruby and Pfizer’s product.
“That is the one oral stabilizer with the verbiage ‘near-complete stabilization’ within the label,” he stated. “Nearly all of advantages described downstream within the label stem from this near-complete stabilization. As early as three months, the earliest time level that we all know of, this drugs begins to take motion in opposition to a composite endpoint of cardiovascular hospitalization and loss of life.”
BridgeBio estimates 500,000 sufferers within the U.S. and European Union have ATTR cardiomyopathy, which represents a market alternative of $15 billion to $20 billion. Proper now, that market is dominated by Pfizer, which reported $3.9 billion in tafamidis gross sales within the first 9 months of 2024, a greater than 65% enhance in comparison with the identical interval in 2023. However this market might quickly be cut up amongst a number of merchandise.
Alnylam Prescription drugs develops medication that silence genes, stopping them from inflicting disease-causing proteins. The biotech already markets Amvuttra for treating polyneuropathy brought on by ATTR. However Alnylam has additionally examined Amvuttra, administered as a subcutaneous injection each three months, as a remedy for ATTR cardiomyopathy. On Monday, Alnylam introduced the FDA accepted the corporate’s supplemental new drug utility on this indication, setting a March 23, 2025 goal date for a regulatory resolution. In the meantime, companions AstraZeneca and Ionis Prescription drugs market antisense oligonucleotide drug eplontersen, model identify Wainua, for treating polyneuropathy brought on by ATTR. A Section 3 trial is underway testing the drug in ATTR cardiomyopathy.
In a notice despatched to buyers, Leerink Companions analyst Mani Foroohar stated Attruby’s label was the best-case situation because the indication assertion contains cardiovascular mortality and hospitalization, in line with Pfizer’s product. Moreover, Attruby can stake the declare of being the primary and solely product with a label specifying near-complete stabilization of TTR. That stated, cracking Pfizer’s established market presence will likely be tough. In outcomes of a Leerink survey launched in September, the Pfizer drug was physicians’ remedy of selection for cardiomyopathy brought on by ATTR, given lengthy their lengthy expertise with the product. There was an uptick in desire for gene silencing therapies, however primarily for treating polyneuropathy brought on by the illness, the survey confirmed. Many physicians said they’d swap to a different product provided that a affected person’s situation just isn’t nicely managed by the Pfizer drug.
William Blair analyst Myles Minter stated language in Attruby’s label stating the drug’s skill to scale back cardiovascular loss of life is “a transparent win for BridgeBio.” However Minter famous the absence on the label of any standalone all-cause mortality knowledge, which is completely different than the Pfizer product’s label. Attruby didn’t result in a statistically important profit on all-cause mortality in comparison with a placebo in its pivotal research. Minter stated clinicians the agency spoke with at current cardiovascular conferences proceed to counsel the significance of not solely the magnitude of cardiovascular occasion danger discount, but in addition the timing of the onset of the drug’s impact on condition that cardiomyopathy can progress quickly. He added that TTR-silencing medication are greatest positioned for market differentiation.
“We proceed to view a discount in all-cause mortality on label as a essential distinction to realize main market share in ATTR-CM alongside Pfizer’s tafamidis,” Minter stated. “Given the shortage of all-cause mortality knowledge included within the Attruby label, we consider Pfizer might begin advertising extra particularly round mortality profit claims.”
BridgeBio set Attruby’s wholesale worth at $18,759.12 for a 28-day provide, which works out to about $244,500 yearly. That’s a slight low cost to Pfizer’s product, priced at $267,987 yearly. Nevertheless it’s nonetheless nicely above the $13,600 to $39,000 cost-effectiveness worth vary calculated by the Institute for Scientific and Financial Evaluate, a non-profit group that researches the worth of medication so as to decide what could be a good worth. Kumar stated all sufferers who participated in Attruby’s Section 3 research will proceed to obtain the drug without spending a dime for the remainder of their lives.
Attruby remains to be underneath evaluation in Europe with a regulatory resolution anticipated in 2025. Below a deal struck earlier this yr, Bayer has unique rights to market the drug in Europe for ATTR cardiomyopathy. Bayer shelled out $310 million in upfront and near-term milestone funds; further sales-based milestones weren’t disclosed. BridgeBio can even earn royalties from Bayer’s gross sales of the product.
Picture: Magicmine, Getty Photos